1 Min Read
* REDHILL BIOPHARMA ANNOUNCES INITIATION OF PHASE IIA STUDY WITH ABC294640 (YELIVA®) FOR CHOLANGIOCARCINOMA AT MAYO CLINIC AND MD ANDERSON Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.